Pathological assessment of sentinel lymph node in earlystage
cervical cancer: Results from the prospective SENTIX trial
(CEEGOG-CX01; ENGOT-CX2)

a 2022

Pathological assessment of sentinel lymph node in earlystage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)

CIBULA, D.; C. KÖHLER; S. BAJSOVÁ; Sylvie ŠEBESTOVÁ; I. ZAPARDIEL et al.

Základní údaje

Originální název

Pathological assessment of sentinel lymph node in earlystage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)

Autoři

Vydání

ESMO Congress 2022, 9 - 13 September 2022, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 50.500

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

ISSN

DOI

https://doi.org/10.1016/j.annonc.2022.07.654

UT WoS

000866211600519

Změněno: 22. 12. 2022 10:04, Mgr. Tereza Miškechová

Anotace

V originále

Background Lymph node (LN) involvement is the key factor indicating adjuvant treatment in early-stage cervical cancer patients. Both macrometastases (MAC; >2mm) and micrometastases (MIC; 0.2-2 mm) are considered LN positive (pN1) since a negative impact of MIC similar to MAC has been confirmed by several studies. Although the majority of MIC are detected only by pathological ultrastaging of LN, no international protocol for pathological assessment has been agreed upon and still sparks controversy. Methods SENTIX is a prospective international observational study on sentinel lymph node (SLN) biopsy in cervical cancer patients conducted in 47 sites of 18 countries. Enrolled were patients with stage T1A1/L1 – T1B1 (<4 cm or ≤ 2 cm for fertility sparing; FIGO2018), common tumour types, no suspicious LN on imaging, and bilateral SLN detection. All detected SLN were intraoperatively examined by one section (standard assessment), and consequently processed by intensive protocol of pathological ultrastaging (2 mm slices embedded in paraffin; paraffin blocks sectioned completely in 150 μm intervals; two sections from each level, one stained with H&E and second examined immunohistochemically). Pathological SLN samples from randomly selected patients from each site were submitted for central quality assessment. Results Out of 647 prospectively enrolled patients, 82 were pN1 (12.7%), 43 with MAC and 39 with MIC (largest type of metastasis). Standard assessment detected only 56.1% of pN1 cases (83.7% MAC; 25.6% MIC) (Table). Additional 22 patients were diagnosed with isolated tumour cells (ITC; <0.2mm), 20 of them found by ultrastaging.

Citovat

CIBULA, D.; C. KÖHLER; S. BAJSOVÁ; Sylvie ŠEBESTOVÁ; I. ZAPARDIEL; G. DI MARTINO; L. R. VAN LONKHUIJZEN; B. SEHNAL; O. ARENCIBIA SÁNCHEZ; B. GIL IBAÑEZ; F. MARTINELLI; J. PRESL; Luboš MINÁŘ; R. MAREK; P. KASCAK; P. HAVELKA; M. MICHAL; T. VAN GORP; K. NEMEJCOVA a R. KOCIAN. Pathological assessment of sentinel lymph node in earlystage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2). In ESMO Congress 2022, 9 - 13 September 2022. 2022. ISSN 0923-7534. Dostupné z: https://doi.org/10.1016/j.annonc.2022.07.654.

@proceedings{2241363,
   author = {Cibula, D. and Köhler, C. and Bajsová, S. and Šebestová, Sylvie and Zapardiel, I. and Di Martino, G. and van Lonkhuijzen, L. R. and Sehnal, B. and Arencibia Sánchez, O. and Gil Ibañez, B. and Martinelli, F. and Presl, J. and Minář, Luboš and Marek, R. and Kascak, P. and Havelka, P. and Michal, M. and Van Gorp, T. and Nemejcova, K. and Kocian, R.},
   booktitle = {ESMO Congress 2022, 9 - 13 September 2022},
   doi = {https://doi.org/10.1016/j.annonc.2022.07.654},
   language = {eng},
   title = {Pathological assessment of sentinel lymph node in earlystage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)},
   url = {https://www.annalsofoncology.org/article/S0923-7534(22)02505-4/fulltext#%20},
   year = {2022}
}

TY  - CONF
ID  - 2241363
AU  - Cibula, D. - Köhler, C. - Bajsová, S. - Šebestová, Sylvie - Zapardiel, I. - Di Martino, G. - van Lonkhuijzen, L. R. - Sehnal, B. - Arencibia Sánchez, O. - Gil Ibañez, B. - Martinelli, F. - Presl, J. - Minář, Luboš - Marek, R. - Kascak, P. - Havelka, P. - Michal, M. - Van Gorp, T. - Nemejcova, K. - Kocian, R.
PY  - 2022
TI  - Pathological assessment of sentinel lymph node in earlystage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)
UR  - https://www.annalsofoncology.org/article/S0923-7534(22)02505-4/fulltext#%20
N2  - Background Lymph node (LN) involvement is the key factor indicating adjuvant treatment in early-stage cervical cancer patients. Both macrometastases (MAC; >2mm) and micrometastases (MIC; 0.2-2 mm) are considered LN positive (pN1) since a negative impact of MIC similar to MAC has been confirmed by several studies. Although the majority of MIC are detected only by pathological ultrastaging of LN, no international protocol for pathological assessment has been agreed upon and still sparks controversy. Methods SENTIX is a prospective international observational study on sentinel lymph node (SLN) biopsy in cervical cancer patients conducted in 47 sites of 18 countries. Enrolled were patients with stage T1A1/L1 – T1B1 (<4 cm or ≤ 2 cm for fertility sparing; FIGO2018), common tumour types, no suspicious LN on imaging, and bilateral SLN detection. All detected SLN were intraoperatively examined by one section (standard assessment), and consequently processed by intensive protocol of pathological ultrastaging (2 mm slices embedded in paraffin; paraffin blocks sectioned completely in 150 μm intervals; two sections from each level, one stained with H&E and second examined immunohistochemically). Pathological SLN samples from randomly selected patients from each site were submitted for central quality assessment. Results Out of 647 prospectively enrolled patients, 82 were pN1 (12.7%), 43 with MAC and 39 with MIC (largest type of metastasis). Standard assessment detected only 56.1% of pN1 cases (83.7% MAC; 25.6% MIC) (Table). Additional 22 patients were diagnosed with isolated tumour cells (ITC; <0.2mm), 20 of them found by ultrastaging.
ER  -

CIBULA, D.; C. KÖHLER; S. BAJSOVÁ; Sylvie ŠEBESTOVÁ; I. ZAPARDIEL; G. DI MARTINO; L. R. VAN LONKHUIJZEN; B. SEHNAL; O. ARENCIBIA SÁNCHEZ; B. GIL IBAÑEZ; F. MARTINELLI; J. PRESL; Luboš MINÁŘ; R. MAREK; P. KASCAK; P. HAVELKA; M. MICHAL; T. VAN GORP; K. NEMEJCOVA a R. KOCIAN. Pathological assessment of sentinel lymph node in earlystage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2). In \textit{ESMO Congress 2022, 9 - 13 September 2022}. 2022. ISSN~0923-7534. Dostupné z: https://doi.org/10.1016/j.annonc.2022.07.654.

Přehled o publikaci